Home
>
National Drug Code (NDC)
>
Lamivudine and Zidovudine
Lamivudine and Zidovudine - 60760-385-04 - (Lamivudine and Zidovudine)
Drug Information of Lamivudine and Zidovudine
| Product NDC: | 60760-385 |
| Proprietary Name: | Lamivudine and Zidovudine |
| Non Proprietary Name: | Lamivudine and Zidovudine |
| Active Ingredient(s): | 150; 300 mg/1; mg/1 & nbsp; Lamivudine and Zidovudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of Lamivudine and Zidovudine
| Product NDC: | 60760-385 |
| Labeler Name: | St Marys Medical Park Pharmacy |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA079081 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120829 |
Package Information of Lamivudine and Zidovudine
| Package NDC: | 60760-385-04 |
| Package Description: | 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-385-04) |
NDC Information of Lamivudine and Zidovudine
| NDC Code | 60760-385-04 |
| Proprietary Name | Lamivudine and Zidovudine |
| Package Description | 4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (60760-385-04) |
| Product NDC | 60760-385 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Lamivudine and Zidovudine |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20120829 |
| Marketing Category Name | ANDA |
| Labeler Name | St Marys Medical Park Pharmacy |
| Substance Name | LAMIVUDINE; ZIDOVUDINE |
| Strength Number | 150; 300 |
| Strength Unit | mg/1; mg/1 |
| Pharmaceutical Classes | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
